Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study

Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant ... Read More